title: Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature.
abstract: Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can be predicted based on mutational status, eculizumab levels, or other testing.
authors.affiliation: Department of Internal Medicine University of Arizona College of Medicine Phoenix Phoenix Arizona USA.
authors.forename: Nick
authors.initials: N
authors.lastname: Thomson
authors.affiliation: Department of Hematology/Oncology Banner MD Anderson Cancer Center Gilbert Arizona USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Ulrickson
keywords: Atypical hemolytic uremic syndrome; eculizumab; thrombotic microangiopathies